Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 單克隆抗體
  4. PD-L2 Monoclonal Antibody

PD-L2 Monoclonal Antibody

  • 中文名稱：
    PD-L2鼠單克隆抗體
  • 貨號(hào)：
    CSB-MA017667A0m
  • 規(guī)格：
    ￥1320
  • 圖片：
    • Western Blot
      Positive WB detected in: HepG2 whole cell lysate, Hela whole cell lysate, PC-3 whole cell lysate, A549 whole cell lysate
      All lanes PD-L2 antibody at 1:2000
      Secondary
      Goat polyclonal to mouse IgG at 1/50000 dilution
      Predicted band size: 31,21 KDa
      Observed band size: 45-50 KDa
      Exposure time:5min  
    • Western Blot
      Positive WB detected in: Hela whole cell lysate at 20μg, 10μg, 5μg, 2.5μg, 1.25μg
      All lanes: PD-L2 antibody at 1:2000
      Secondary
      Goat polyclonal to mouse IgG at 1/50000 dilution
      Predicted band size: 31,21 KDa
      Observed band size: 45-50 KDa
      Exposure time:5min  
    • Western Blot
      Positive WB detected in: 15μg hela whole cell lysate PD-L2 antibody at 1:5000, 1:10000, 1:20000, 1:40000, 1:80000, 1:160000, 1:320000, 1:640000
      Secondary
      Goat polyclonal to mouse IgG at 1/50000 dilution
      Predicted band size: 31,21 KDa
      Observed band size: 45-50 KDa
      Exposure time:5min
    • IHC image of CSB-MA017667A0m diluted at 1:100 and staining in paraffin-embedded human tonsil tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.
    • Immunofluorescence staining of HepG2 cells with CSB-MA017667A0m at 1:100, counter-stained with DAPI. The cells were incubated with the antibody overnight at 4°C. Nuclear DNA was labeled in blue with DAPI. The secondary antibody was FITC-conjugated AffiniPure Goat Anti-Mouse IgG (H+L).
    • Immunofluorescence staining of Hela cells with CSB-MA017667A0m at 1:100, counter-stained with DAPI. The cells were incubated with the antibody overnight at 4°C. Nuclear DNA was labeled in blue with DAPI. The secondary antibody was FITC-conjugated AffiniPure Goat Anti-Mouse IgG (H+L).
    • Immunofluorescence staining of Raji cells with CSB-MA017667A0m at 1:100, counter-stained with DAPI. The cells were incubated with the antibody overnight at 4°C. Nuclear DNA was labeled in blue with DAPI. The secondary antibody was FITC-conjugated AffiniPure Goat Anti-Mouse IgG (H+L).
    • Immunofluorescence staining of U251 cells with CSB-MA017667A0m at 1:100, counter-stained with DAPI. The cells were incubated with the antibody overnight at 4°C. Nuclear DNA was labeled in blue with DAPI. The secondary antibody was FITC-conjugated AffiniPure Goat Anti-Mouse IgG (H+L).
    • Overlay histogram showing 293 cells transfected with PD-L2 stained with CSB-MA017667A0m (red line). The cells were incubated in 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (2µg/1*106cells) for 1 h at 4°C. The secondary antibody used was R-PE-conjugated Goat Anti-Mouse IgG(H+L) at 1/100 dilution for 30min at 4°C. Isotype control antibody (green line) was mouse IgG2b (2µg/1*106cells) used under the same conditions. Acquisition of >10,000 events was performed.
    • Immunoprecipitating PD-L2 in Hela whole cell lysate
      Lane 1: Mouse control IgG instead of CSB-MA017667A0m in Hela whole cell lysate
      Lane 2: CSB-MA017667A0m (2µl) + Hela whole cell lysate (500µg)
      Lane 3: Hela whole cell lysate (20µg)
      For western blotting, the blot was detected with CSB-MA017667A0m at 1:2000, and a HRP-conjugated Protein G antibody was used as the secondary antibody at 1:2000
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：

    The recombinant human PD-L2 protein (21-118aa) was used to immunze a mouse to stimulate its immune system. After that, PD-L2 antibody-secreting B cells were isolated from the immunized mouse and then fused with myeloma cells to get the hybridomas. Hybridomas secreting PD-L2 antibody were selected and injected into the abdominal cavity of mice. After a period of time, mice ascites were collected, which contained a large amount of PD-L2 monoclonal antibody. The PD-L2 monoclonal antibody underwent protein A purification and got a purity of above 95%. It can be used to detect human PD-L2 protein in ELISA, WB, IHC, IF, FC, and IP applications.

    PD-L2 binds to its receptor PD-1 on the surface of T cells and regulates T cell activation and tolerance. PD-L2 functions as a negative regulator of T cell responses by inducing T cell apoptosis, suppressing T cell proliferation, and reducing cytokine production. It plays a key role in maintaining immune homeostasis and preventing autoimmunity by limiting the activation of self-reactive T cells. PD-L2 is also involved in the regulation of immune responses to tumors and infectious agents.

  • 產(chǎn)品名稱：
    Mouse anti-Homo sapiens (Human) PDCD1LG2 Monoclonal Antibody antibody
  • Uniprot No.：
  • 基因名：
  • 別名：
    B7 dendritic cell molecule antibody; B7-DC antibody; B7DC antibody; bA574F11.2 antibody; Btdc antibody; Butyrophilin B7 DC antibody; Butyrophilin B7-DC antibody; Butyrophilin B7DC antibody; CD 273 antibody; CD273 antibody; CD273 antigen antibody; MGC142238 antibody; MGC142240 antibody; PD 1 ligand 2 antibody; PD L2 antibody; PD-1 ligand 2 antibody; PD-L2 antibody; PD1 ligand 2 antibody; PD1L2_HUMAN antibody; PDCD 1 ligand 2 antibody; PDCD1 ligand 2 antibody; PDCD1L2 antibody; Pdcd1lg2 antibody; PDL 2 antibody; PDL2 antibody; Programmed cell death 1 ligand 2 antibody; Programmed death ligand 2 antibody
  • 宿主：
    Mouse
  • 反應(yīng)種屬：
    Human
  • 免疫原：
    Recombinant Human Programmed cell death 1 ligand 2 protein (21-118AA)
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標(biāo)記方式：
    Non-conjugated
  • 克隆類型：
    Monoclonal Antibody
  • 抗體亞型：
    IgG2b
  • 純化方式：
    >95%,Protein A purified
  • 克隆號(hào)：
    7F11D11
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    Preservative: 0.03% Proclin 300
    Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
  • 產(chǎn)品提供形式：
    Liquid
  • 應(yīng)用范圍：
    ELISA, WB, IHC, IF, FC, IP
  • 推薦稀釋比：
    Application Recommended Dilution
    WB 1:5000-1:640000
    IHC 1:50-1:200
    IF 1:50-1:200
    FC 1:50-1:200
    IP 2μl-5μl
  • Protocols：
  • 儲(chǔ)存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

  • 功能：
    Involved in the costimulatory signal, essential for T-cell proliferation and IFNG production in a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production.
  • 基因功能參考文獻(xiàn)：
    1. Our results confirm and extend prior studies of PD-L1 and provide new data of PD-L2 expression in lymphomas PMID: 29122656
    2. High PD-L2 expression may be a target of immunotherapy in patients with PD-L1-negative Non-small Cell Lung Cancer. PMID: 30275216
    3. The high-affinity PD-1 mutant could compete with the binding of antibodies specific to PD-L1 or PD-L2 on cancer cells. PMID: 29890018
    4. the binding affinities of the PD-1-PD-L1/PD-L2 co-inhibitory receptor system, was characterized. PMID: 27447090
    5. Tumor PDCD1LG2 expression is inversely associated with Crohn-like lymphoid reaction to colorectal cancer, suggesting a possible role of PDCD1LG2-expressing tumor cells in inhibiting the development of tertiary lymphoid tissues during colorectal carcinogenesis. PMID: 29038297
    6. The biopsy tumor key protein measurements demonstrate substantial between-tumor variation in expression ratios of these proteins and suggest that programmed cell death 1 ligand 2 PD-L2 is present in some tumors at levels sufficient to contribute to programmed cell death-1 PD-1-dependent T-cell regulation and possibly to affect responses to PD-1- and programmed cell death 1 ligand 1 PD-L1-blocking drugs. PMID: 28546465
    7. the positive rate of PD-L2 did not show any differences between primary tumors and metastatic lymph nodes. In multivariate analysis, PD-L1 expression, PD-L2 expression, a low density of CD8(+) T cells in primary tumors, and PD-1 expression on CD8(+) T cells in primary tumors were associated with poor prognosis. PMID: 28754154
    8. in some tumor types, PD-L2 expression is more closely linked to Th1/IFNG expression and PD-1 and CD8 signaling than PD-L1 PMID: 27837027
    9. Clinical response to pembrolizumab in patients with head and neck squamous cell carcinoma (HNSCC)may be related partly to blockade of PD-1/PD-L2 interactions. Therapy targeting both PD-1 ligands may provide clinical benefit in these patients. PMID: 28619999
    10. PD-L2 is regulated by both interferon beta and gamma signaling. PMID: 28494868
    11. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma PMID: 27456947
    12. Data suggest that hormonal 1,25-dihydroxyvitamin D is a direct transcriptional inducer of genes encoding PDL1 and PDL2 in myeloid cells/macrophages; this up-regulation of gene expression appears to be species- and cells-specific. PMID: 29061851
    13. PD-L2 copy number gains were not related to PD-L2 augmentation in non-small cell lung cancer. PMID: 27050074
    14. PD-L2 expression has been reported in 52% of esophageal adenocarcinomas but little is known about the expression of other immune checkpoints PMID: 28561677
    15. Low PD-L2 expression is associated with pediatric solid tumors. PMID: 28488345
    16. this study shows that higher PD-L2 expression on blood dendritic cells, from Plasmodium falciparum-infected individuals, correlates with lower parasitemia PMID: 27533014
    17. PD-L1/PD-L2 copy number alterations are a defining feature of classical Hodgkin lymphoma. PMID: 27069084
    18. PDL2 was overexpressed in Epstein Barr virus-associated gastric adenocarcinoma. PMID: 26980034
    19. higher expression of PD-L1 and PD-L2 on CD1a(+) cells than that on CD83(+) cells in cutaneous squamous cell carcinoma tumour tissues may contribute to negative regulation in anti-tumour immune responses PMID: 28052400
    20. stable ectopic expression of wild-type PDCD1LG2 and the PDCD1LG2-IGHV7-81 fusion showed, in coculture, significantly reduced T-cell activation. PMID: 27268263
    21. The expression levels of PD-1, PD-L1 and PD-L2 in CD3(+) T cells and CD19(+) B cells and serum IFN-gamma level in progressive hepatocellular carcinoma patients were significantly higher than controls. PMID: 27609582
    22. Downregulation of the immunosuppressive molecules, PD-1 and PD-L1, may imply that over-activation of immune cells in multiple sclerosis occurs through signaling dysfunction of these molecules and PD-L2 plays no important role in this context PMID: 27921410
    23. an IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma PMID: 27564404
    24. High PD-L2 expression is associated with Renal Cell Carcinoma. PMID: 26464193
    25. knocking down in dendritic cells results in activation of inflammatory T cells PMID: 26599163
    26. We observed cogain or coamplification of CD274 and PDCD1LG2 in 32 of 48 cervical and 10 of 23 vulvar squamous cell carcinomas PMID: 26913631
    27. PD-L2 expression was neither associated with VEGF-TKI responsiveness nor patients' outcome PMID: 26424759
    28. PD-L1 and PD-L2 are useful new markers for identifying select histiocyte and dendritic cell disorders and reveal novel patient populations as rational candidates for immunotherapy PMID: 26752545
    29. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. PMID: 26317899
    30. the inflammatory environment in Barrett's esophagus and esophageal adenocarcinoma may contribute to the expression of PD-L2. PMID: 26081225
    31. PDL2 could promote the ability of human placenta-derived mesenchymal stromal cells to augment the secretion of IL-10. PMID: 26432559
    32. We suggest that decreased expression of programmed death-ligand 1, 2 on psoriatic epidermis can contribute to its chronic unregulated inflammatory characteristics. PMID: 26133691
    33. Suggest role for PD-L2 in recurrence of hepatitis C infection post orthotopic liver transplantation. PMID: 25675203
    34. Report PD-L2 expression in breast neoplasms. PMID: 26541326
    35. Data indicate that pulmonary pleomorphic carcinoma (PC) very frequently express CD274 antigen (PD-L1) and CD273 antigen (PD-L2). PMID: 26329973
    36. PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma is associated with an increased number of CD8(+) tumor infiltrating lymphocytess and increased MET expression. PMID: 25662388
    37. Results show that human-derived chordoma cell lines demonstrate inducible expression of PD-L1 and PD-L2, and that primary chordoma tissue shows variable expression of PD-1 and PD-L1 in infiltrating immune cells PMID: 25349132
    38. conclude that PD-L2 protein is robustly expressed by the majority of primary mediastinal (thymic) large B-cell lymphomas PMID: 25025450
    39. PD-1/PD-Ls pathways on PMCs inhibited proliferation and adhesion activity of CD4+ T cells, suggesting that Mycobacterium tuberculosis might exploit PD-1/PD-Ls pathways to evade host cell immune response in human. PMID: 24406080
    40. High Expression of PD-L2 is associated with myelodysplastic syndromes. PMID: 24270737
    41. Data indicate that the bone morphogenetic proteins (BMPs) signaling pathway regulates PD-L1 and PD-L2 expression in monocyte-derived dendritic cells (MoDCs) during the maturation process. PMID: 24532425
    42. Recurrent genomic rearrangement events in CD274 and PDCD1LG2 underlie an immune privilege phenotype in a subset of B-cell lymphomas. PMID: 24497532
    43. PD-L1 and PD-L2 expressed on hPMSCs could inhibit the hPMSCs-mediated up-regulation on the expression of IL-17 secreted by peripheral blood T cells PMID: 23388330
    44. Macrophages from infected animals show increased expression of PDL2 and CD80 that was dependent from the sex of the host. PMID: 23533995
    45. expression of PD-1 and its ligands, PD-L1 and PD-L2, in liver biopsies from HBV-related acute-on-chronic liver failure (HBV-ACLF) and chronic hepatitis B (CHB) patients were analyzed; results showed all 3 molecules were observed in the HBV-ACLF samples and levels were significantly higher than in CHB PMID: 22895698
    46. Data show that PD-1, PD-L1, PD-L2, CCL17, and CCL22 mRNA was identified in papillomas. PMID: 22322668
    47. Data suggest that brain endothelial cells contribute to control T cell transmigration into the CNS and immune responses via PD-L2 but not PD-L1 expression. PMID: 22067141
    48. increased expression of PD-L2, as a costimulatory molecule, may have an important modulatory function on the local immune responses of OLP in vivo. PMID: 21457347
    49. Data suggest that PD-L1 may contribute to negative regulation of the immune response in chronic hepatitis B, and that PD-1 and PD-L1 and 2 may play a role in immune evasion of tumors. PMID: 21876620
    50. Our results suggest that PD-1 G-536A, PD-L1 A8923C and PD-L2 C47103T polymorphisms are associated with the presence of ankylosing spondylitis. PMID: 21791547

    顯示更多

    收起更多

  • 亞細(xì)胞定位：
    [Isoform 3]: Secreted.; [Isoform 2]: Endomembrane system; Single-pass type I membrane protein.; [Isoform 1]: Cell membrane; Single-pass type I membrane protein.
  • 蛋白家族：
    Immunoglobulin superfamily, BTN/MOG family
  • 組織特異性：
    Highly expressed in heart, placenta, pancreas, lung and liver and weakly expressed in spleen, lymph nodes and thymus.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 18731

    OMIM: 605723

    KEGG: hsa:80380

    STRING: 9606.ENSP00000380855

    UniGene: Hs.532279